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Radiation therapy (RT) is advocated in the multimodal treatment of high-grade soft tissue sarcoma (STS), but its role may be less
clear in chemotherapy-sensitive STS such as extraskeletal Ewing sarcoma (EES). e purpose of this study was to determine the
role of RT on overall survival (OS) in localized EES adult patients treated with chemotherapy and surgery. Adult patients
diagnosed with EES and reported to the National Cancer Database from 2004 to 2014 were evaluated. All patients were treated
with surgical resection. Patient demographics, tumor characteristics, treatments received, resection margins, and survival were
examined for the 232 patients identified. Using multivariate analysis and Cox proportional hazard analysis, predictors of OS were
determined. In the overall cohort, 40 percent of patients received RT and 78 percent received chemotherapy, with 31 percent
receiving both. e addition of RT to the patients receiving surgery + chemotherapy did not improve OS (p< 0.05). Twenty-four
percent of patients who achieved R0 resection after surgery still received RT without any improvement in OS. Patients treated at
community cancer centers were more likely to receive additional RTcompared with Comprehensive Cancer Centers (p< 0.05). In
adult EES patients with localized disease treated with chemotherapy and surgery, the addition of RT does not improve
overall survival.
1. Introduction
Ewing sarcoma consists of a group of tumors characterized
by morphologically similar round-cell neoplasms derived
from undifferentiated mesenchymal cells with the potential
for neuroectodermal differentiation [1–4]. Extraskeletal
Ewing sarcoma (EES) is a rare soft tissue sarcoma (STS),
with an incidence of 1 in 5–10 million and represents a small
portion of the 12,000 annual STS roughly [5–8]. Due to the
rarity of EES, few large population-based studies exist that
address treatment strategies and associated clinical out-
comes, especially in adults [9–11]. e largest studies to
investigate EES compared outcomes relative to skeletal
Ewing sarcoma without particular analysis of treatment
modalities specific to EES [7, 12–19].
Historically, patients with EES were treated with a
rhabdomyosarcoma protocol but current evidence suggests
that these patients benefit from skeletal Ewing sarcoma
protocols instead [20, 21]. e National Comprehensive
Cancer Network (NCCN) does not differentiate the treat-
ment of EES from skeletal Ewing sarcoma [22]. Standard of
care guidelines for treatment of osseous and extraosseous
Ewing sarcoma include multiagent chemotherapy prior to
local control treatment for nonmetastatic disease [23].
Accepted local control treatment can consist of (1) R0 re-
section, (2) R1 resection + radiation therapy (RT), or (3) RT
and concurrent chemotherapy [23]. Typically, local treat-
ment with surgery alone is preferred if this can be performed
with acceptable morbidity. Ewing sarcoma is more common
in young patients where the risk of RT-associated secondary
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malignancies is higher [24]. In addition, some data may
suggest that surgery is favorable compared to RT for Ewing
sarcoma [25, 26].
As the multimodal treatment of STS has evolved, limb
salvage has become feasible in approximately 95% of cases
with RT playing a key role in these multimodal treatment
protocols [27, 28]. Recent literature demonstrates that about
half of all patients with EES receive RT [29]. However,
radiation-associated complications such as joint contracture,
muscle atrophy, pathologic fractures, and secondary ma-
lignancies occurring in 10 percent to up to 63 percent of
patients receive RT for sarcomas [2]. e role of RT in adult
STS has recently been reviewed, with a large-scale NCDB
analysis demonstrating improvements in R0 resection and
overall survival (OS) in STS [30]. e analysis did not
differentiate between histologic types of STS. is is im-
portant as EES is an STS with an above average favorable
response to chemotherapy [8].e histologic specific impact
of RT on survival, especially in chemotherapy-sensitive
diseases such as EES, remains unclear.
e purpose of this study was to examine the role of RT
on overall survival in adult EES patients treated with che-
motherapy + surgery. Using data from the National Cancer
Database (NCDB), we aimed to determine predictors for the
use of RT and if the addition of RT is associated with in-
creased OS for patients with EES treated with chemo-
therapy + local control surgery. We hypothesized that the
addition of RT does not improve OS in adult EES patients
treated with chemotherapy + local control surgery.
2. Materials and Methods
Using the NCDB, patients with histological diagnosed EES
were identified between the years of 2004 and 2014. EES in
the NCDB was classified according to the International
Classification of Childhood Cancer and/or the International
Classification of Disease for Oncology, third revision. A
limitation of this database though is that the presence of
EWSR1 rearrangement is not documented. Patients less than
18 years of age and patients with unknown skeletal versus
extraskeletal status, surgical margin status, tumor size, vital
status, chemotherapy status, and/or radiotherapy status were
excluded. Patients with metastases were excluded as well as
patients with a histologic grade less than 3 as EES represents
a high-grade disease; this represents either an incorrect
diagnosis or grading. Overall, 232 patients were included in
the final analysis. All patients underwent surgical resection
for local control. Variables were based on clinical signifi-
cance and included age, sex, race, year of diagnosis, facility
type, Charlson–Deyo score, grade, tumor size, surgical
margins, receipt of chemotherapy, and receipt of radio-
therapy to the tumor site. Summary statistics were reported
as means with standard deviation.
Standard multivariate analysis was performed to de-
termine the predictors of patients receiving RT. Multivariate
logistic regression was performed to evaluate RT as a pre-
dictor of R0 resection. Cox proportional hazard models were
used to assess the effect of the different variables on OS while
controlling for known prognostic factors. OS from time of
diagnosis was estimated using the Kaplan–Meier method
and expressed as Kaplan–Meier estimates with 95 percent
confidence intervals. OS was measured from time of di-
agnosis to time of last contact or death, in months. Disease-
specific survival is not captured in the NCDB dataset. All
statistical analyses were performed using Stata version 14
(StataCorp LP, College Station, TX). Significance was set at
p< 0.05 using a two-tailed t-test. All patient information was
deidentified and, therefore, exempted from the University of
California, Davis, Institutional Review Board approval.
3. Results
e patient demographics and clinical demographics of the
232 patients with EES are depicted in Table 1. Overall, 13
percent of patients (31/232) received only surgery, 9 percent
(20/232) received surgery + RT, 47 percent (108/232) re-
ceived surgery + chemotherapy, and 31 percent (73/232)
received surgery + chemotherapy +RT. In total, 40 percent
of all patients (93/232) received RT and 78 percent of all
patients (181/232) received chemotherapy. ere were no
significant differences in patient demographics between
patients that received RT and those that did not.
Multivariate regression analysis for predictors of re-
ceiving RTrevealed no specific variables that were associated
with increased probability of receiving RT other than R1
resection and being treated at the Community Cancer
Program (p< 0.05). Of patients who underwent an R0 re-
section, 24 percent still received postoperative RT. Com-
munity Cancer Programs were more likely to treat adult EES
patients with surgery + chemo+RT compared to Compre-
hensive Community Cancer Programs, Academic/Research
Programs, or Integrated Network Cancer Programs
(p< 0.008).
e Cox proportional hazard analysis for survival dem-
onstrated that a tumor size greater than 10 cm was associated
with worse OS (HR 1.93, 95% CI 1.14–3.28, p � 0.014). R0
resection was not associated with improved OS. In the overall
cohort, chemotherapy was associated with improved OS (HR
0.575, 95% CI 0.338–0.978, p< 0.041). In the overall cohort,
RTwas associated with improved OS, but in subset analysis of
the 181 patients who received chemotherapy, the addition of
radiotherapy was no longer associated with improved survival
(Figure 1). Patients who received only surgery had signifi-
cantly decreased 5-year OS compared to patients who re-
ceived surgery + chemotherapy±RT (p< 0.032) (Figure 2). In
patients who received an R1 resection, radiation therapy was
not associated with improved survival (median survival
25.8months vs. 26.3months, p � 0.52).
4. Discussion
EES represents a rare high-grade STS, and therefore, limited
literature exists examining treatment strategies. Our study
represents the first large population-based study, in-
vestigating the role of RT in treatment of EES and overall
survival in adult patients with localized disease receiving
chemotherapy + surgery. A recent large population-based
study compared pediatric to adult patients with Ewing
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Table 1: Patient demographics and tumor characteristics.
No. of RTs (144) Pre-op RT (14) Post-op RT (79) p value
Age 40.51 ±16.85 46.71 ±15.36 38.25 ±15.46 ns
N Percent N Percent N Percent
Sex
Male 72 50.00 9 64.29 43 54.43 ns
Female 72 50.00 5 35.71 36 45.57 ns
Race
White 130 90.28 12 85.71 71 89.87 ns
Black 8 5.56 0 0.00 3 3.80 ns
American Indian, Aleutian, or Eskimo 2 1.39 0 0.00 0 0.00 ns
Asian 1 0.69 0 0.00 3 3.80 ns
Pacific islander 2 1.39 1 7.14 0 0.00 ns
Others 1 0.69 0 0.00 2 2.53 ns
Grade
Grade 1 3 2.08 0 0.00 2 2.53 ns
Grade 2 3 2.08 0 0.00 1 1.27 ns
Grade 3 83 57.64 8 57.14 34 43.04 ns
Grade 4 55 38.19 6 42.86 42 53.16 ns
Tumor size (categorical)<5 cm 48 33.26 1 7.14 31 39.30 ns
5–10 cm 62 43.02 4 28.57 34 43.08 ns>10–15 cm 22 15.26 7 50.00 9 11.42 ns>15 cm 12 8.29 2 14.28 5 6.34 ns
Charlson–Deyo Score
0 122 84.72 14 100.00 71 89.87 ns
1 18 12.50 0 0.00 7 8.86 ns>1 4 2.78 0 0.00 1 1.27 ns
Margins
R0 122 84.72 12 85.71 58 73.42 ns
R1 18 12.50 2 14.29 13 16.46 ns
R2 4 2.78 0 0.00 8 10.13 ns
Chemo
Not given 31 21.53 5 35.71 15 18.99 ns
Given 108 75.00 9 64.29 64 81.01 ns
Unknown 5 3.47 0 0.00 0 0.00 ns
Facility type
Community cancer program 2 1.39 0 0.00 3 3.80 ns
Comprehensive community cancer program 17 11.81 2 14.29 10 12.66 ns
Academic/research program 43 29.86 3 21.43 21 26.58 ns
Integrated network cancer program 2 1.39 4 28.57 3 3.80 ns
















Figure 1: Kaplan–Meier overall survival curves for patients
















Figure 2: Kaplan–Meier overall survival for patients treated with
surgery with and without chemotherapy regardless of radiotherapy
treatment.
Sarcoma 3
sarcoma with subset analysis of extraskeletal locations using
the Surveillance, Epidemiology, and End Results (SEER)
database and determined that RT was not associated with
improved OS in pediatric or adult patients undergoing
surgery [31]. ere was no analysis of RT in regard to local
control. However, chemotherapy was not able to be analyzed
as these data are not present in the SEER database [31]. In
comparison, the NCDB allowed us to evaluate the role of RT
in patients receiving chemotherapy + surgery for local
control. is study aimed to specifically examine those
patients who received chemotherapy + surgery and de-
termine if RT added extra benefit for OS.
e NCCN standard of care guidelines for treatment of
localized EES includes multiagent chemotherapy for at least
12weeks prior to local therapy with accepted local therapy
consisting of (1) R0 resection, (2) R1 resection +RT, or (3) RT
and concurrent chemotherapy [23]. Surprisingly, 22 percent
of patients did not receive chemotherapy at all; the reason for
this deviation from NCCN guideliens is unclear, and further
investigation is warranted as chemotherapy is critical for
treatment and OS. RT alone is an acceptable treatment for
local control as well, but some evidence has suggested that
surgery improved outcomes [32]. Ahmed et al. showed that
patients who underwent surgical resection, whether wide or
less than wide, had improved survival compared to patients
who did not have surgery [33]. In accordance with the prior
literature, our study did not find an association between R0
surgical resection and overall survival [29, 34–37]. e prior
literature noted that 42% of patients with EES receive RT,
which correlated with our study where 40% of patients re-
ceived RT [18]. However, almost 25% of patients with R0
resection received postoperative RT without indication and
despite NCCN guidelines. is may be due to some in-
stitutions following generalized high-grade STS local therapy
algorithms for extraskeletal bone tumors. ere is ongoing
debate for these tumor types regarding whether skeletal and
extraskeletal Ewing should be treated exactly the same. e
addition of RT in R0 patients may be related to the finding
that Community Cancer Programs were more likely to treat
adult EES patients with surgery + chemo+RT than compared
to Comprehensive Community Cancer Programs, Academic/
Research Programs, or Integrated Network Cancer Programs.
Further research investigating the cause of the increased
prevalence of RT in addition to surgery and chemotherapy is
warranted amongst Community Cancer Programs. Addi-
tionally, given that postoperative RTfor R0 resection does not
improve OS, further examination of why nearly 25% of R0
patients still receive RT in EES is needed. e addition of RT
in this subset of patients may represent overtreatment,
resulting in risk of increased morbidity. However, other in-
stitutions and/or physicians may argue that EES should be
treated more as an STS than an osseous tumor in a soft tissue
environment, and in that case, RT may be a crucial local
therapy agent regardless of outcomes on OS.
e 5-year OS for all patients in the study was
28.4% but improved to 51% for patients treated with
surgery + chemotherapy±RT. is is consistent with the
recent literature demonstrating 5-year OS ranges from ap-
proximately 50 to 70 percent [42–45]. Chemotherapy
administration was associated with improved OS regardless of
resectionmargin or tumor size. However, the addition of RTto
surgery + chemotherapy did not affect OS. Hence, the role of
RT with regard to survival outcomes in chemotherapy sen-
sitive, high-grade STS treated with chemotherapy, and local
control surgery remains questionable. In the Intergroup
Rhabdomyosarcoma Study, of the 130 children with EES,
those treated with surgery + chemotherapy+ radiotherapy did
not have improved OS compared to those treated with sur-
gery + chemotherapy [38]. Our study demonstrates that the
vast majority of patients with EES receive chemo-
therapy+ local control surgery, and subsequently, the addition
of RT did not improve OS in these patients.
ere are important limitations of our study to rec-
ognize. First, the NCDB does not contain local control data
or disease-specific survival. Secondly, the role of pre-
operative RT in predicting R0 resection could not be de-
termined due to the low number of patients who received
preoperative RT. Specific chemotherapy regimens are not
detailed in the NCDB, and different regimens may affect OS
[39]. Furthermore, translocation status as a confirmatory
diagnostic tool in the Ewing sarcoma family of tumor
diagnosis is not available in the NCDB [40]. Finally, a
limitation inherent to the NCDB as with other large da-
tabases is that the information is self-reported by cancer
treatment facilities and may not be reflective of the
treatment of EES everywhere.
e strength of our study is the relatively large number of
patients with EES in the NCDB. Large studies do exist that
examine the differences in patient characteristics and out-
comes in patients with EES compared to patients with
skeletal Ewing sarcoma, but this study represents the largest
study to investigate specifically the role of RT in OS in the
EES patient treated with surgery + chemotherapy. Further-
more, our study represents a more modern EES treatment
era as our study limits retrospective review of data to 2004
compared to prior studies using the SEER data from as far
back as 1973.
5. Conclusions
Our study determined that, for adult EES patients with
localized disease receiving chemotherapy and surgical re-
section, the addition of RT did not improve survival al-
though we were unable to assess the effect of RT on local
control. Although chemotherapy has been demonstrated to
improve OS and is a mainstay of standard of care for EES, 22
percent of patients did not receive chemotherapy at all.
Furthermore, the type of treatment facility was an important
predictor for the use of RT with community-level programs
more likely to use RT. Over 40 percent of patients with EES
receive RT, including about 25 percent of patients with
negative margins post-op, but without significant im-
provement in their overall survival.
Data Availability
e datasets generated during and/or analyzed during the
current study are not publicly available due to the IRB
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